Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 12, 2011, Pages 25-31

  Kircik, Leon H ^a,b,c,d,e,f   Del Rosso, James Q ^a,b,c,d,e,f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Physicians Skin Care PLLC   (United States)

^d VALLEY HOSPITAL MEDICAL CENTER   (United States)

^e TOURO UNIVERSITY NEVADA   (United States)

^f Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE DERIVATIVE; CERAMIDE DOMINANT PHYSIOLOGICAL LIPID; CORTICOSTEROID; LIPID EMULSION; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; APPLICATION SITE IRRITATION; ARTICLE; ATOPIC DERMATITIS; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; INFANT; INVESTIGATOR GLOBLAL ASSESSMENT RATING SCALE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PAIN; PATIENT SATISFACTION; PEDIATRICS; PRESCHOOL CHILD; PRURITUS; QUALITY OF LIFE; RATING SCALE; SCHOOL CHILD; SKIN IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84855873391     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Chamlin SL, Frieden IJ, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114(3):607-611. (Pubitemid 41529513)
2. Krafchik BR. Atopic dermatitis. http://emedicine.medscape.com/ article/1049085-overview. Accessed September 16, 2010.
3. Horii KA, Simon SD, Liu DY, Sharma V. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics. 2007;190(3):e527-e534. (Pubitemid 47358264)
4. Chamlin SL, Chren MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin N Am. 2010;30:281-288.
5. Alvarenga TM, Caldeira AP. Quality of life in pediatric patients with atopic dermatitis. J Pediatr (Rio J). 2009;85(5):415-420.
6. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-936. (Pubitemid 30304603)
7. Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol. 2004;150:284-290. (Pubitemid 38352466)
8. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122(4): 812-824.
9. Carbone A, Siu A, Patel R. Pediatric atopic dermatitis: a review of the medical management. Ann Pharmacother. 2010;44(9): 1448-1458.
10. Kircik L. A nonsteroidal lamellar matrix cream containing palmyitoylethanolamide of the treatment of atopic dermatitis. J Drugs Dermatol. 2010;9(4):334-338.
11. Leung DYM, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Investig. 2004;113(5):651-657. (Pubitemid 38544154)
12. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009;8(12):1106-1111.
13. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121:1337-1343.
14. Mao-Qiang M, Brown BE, Wu-Pong S, Feingold KR, Elias PM. Exogenous nonphysiologic vs. physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131:809-816.
15. Kircik LH, Del Rosso JQ, Aversa D. Evaluating clinical use of a ceramide-dominant, physiologic lipid-based topical emulsion for atopic dermatitis. J Clin Aesthet Dermatol. 2011. In press.